Clifford A Hudis

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane
    Monica N Fornier
    Breast Cancer Medicine Service, Division of Solid Tumor Oncology, Department of Medicine Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 104:1575-9. 2005
  2. ncbi Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for resectable high-risk breast cancer: feasibility and efficacy
    C Hudis
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Clin Oncol 17:93-100. 1999
  3. ncbi Adjuvant therapy for breast cancer: practical lessons from the early breast cancer trialists' collaborative group
    Clifford A Hudis
    Breast Dis 21:3-13. 2004
  4. ncbi Triple-negative breast cancer: an unmet medical need
    Clifford A Hudis
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York, USA
    Oncologist 16:1-11. 2011
  5. ncbi Current status and future directions in breast cancer therapy
    Clifford A Hudis
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Breast Cancer 4:S70-5. 2003
  6. ncbi Weekly epoetin alfa during adjuvant chemotherapy for breast cancer: effect on hemoglobin levels and quality of life
    Clifford A Hudis
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Breast Cancer 6:132-42. 2005
  7. ncbi Preoperative chemotherapy for breast cancer: miracle or mirage?
    Clifford Hudis
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, Weill College of Medicine, Cornell University, New York, New York 10024, USA
    JAMA 298:2665-7. 2007
  8. ncbi Adjuvant use of taxanes for patients with breast cancer: we see the tip of the iceberg
    Clifford Hudis
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Breast Cancer 3:326-32. 2002
  9. ncbi The best use of adjuvant chemotherapy: new drugs and new use of "old" drugs
    Clifford Hudis
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 206, New York, NY 10021, USA
    Breast 14:570-5. 2005
  10. ncbi rHuEPO and treatment outcomes: the clinical experience
    Clifford A Hudis
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Oncologist 9:55-69. 2004

Research Grants

  1. CANCER AND LEUKEMIA GROUP B
    Clifford Hudis; Fiscal Year: 2007

Detail Information

Publications130 found, 100 shown here

  1. ncbi Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane
    Monica N Fornier
    Breast Cancer Medicine Service, Division of Solid Tumor Oncology, Department of Medicine Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 104:1575-9. 2005
    ....
  2. ncbi Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for resectable high-risk breast cancer: feasibility and efficacy
    C Hudis
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Clin Oncol 17:93-100. 1999
    ..Dose-dense chemotherapy is predicted to be a superior treatment plan. Therefore, we studied dose-dense doxorubicin, paclitaxel, and cyclophosphamide (A-->T-->C) as adjuvant therapy...
  3. ncbi Adjuvant therapy for breast cancer: practical lessons from the early breast cancer trialists' collaborative group
    Clifford A Hudis
    Breast Dis 21:3-13. 2004
  4. ncbi Triple-negative breast cancer: an unmet medical need
    Clifford A Hudis
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York, USA
    Oncologist 16:1-11. 2011
    ..This article will review the clinical problem of triple-negative disease, potential prognostic factors, demonstrated efficacy of currently available therapeutic options, and new potential therapies...
  5. ncbi Current status and future directions in breast cancer therapy
    Clifford A Hudis
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Breast Cancer 4:S70-5. 2003
    ....
  6. ncbi Weekly epoetin alfa during adjuvant chemotherapy for breast cancer: effect on hemoglobin levels and quality of life
    Clifford A Hudis
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Breast Cancer 6:132-42. 2005
    ....
  7. ncbi Preoperative chemotherapy for breast cancer: miracle or mirage?
    Clifford Hudis
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, Weill College of Medicine, Cornell University, New York, New York 10024, USA
    JAMA 298:2665-7. 2007
  8. ncbi Adjuvant use of taxanes for patients with breast cancer: we see the tip of the iceberg
    Clifford Hudis
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Breast Cancer 3:326-32. 2002
    ....
  9. ncbi The best use of adjuvant chemotherapy: new drugs and new use of "old" drugs
    Clifford Hudis
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 206, New York, NY 10021, USA
    Breast 14:570-5. 2005
    ..When available, eligible patients should be enrolled on prospective clinical trials...
  10. ncbi rHuEPO and treatment outcomes: the clinical experience
    Clifford A Hudis
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Oncologist 9:55-69. 2004
    ....
  11. ncbi 5-year results of dose-intensive sequential adjuvant chemotherapy for women with high-risk node-positive breast cancer: A phase II study
    C Hudis
    Breast Cancer Medicine Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 17:1118. 1999
    ....
  12. ncbi Trastuzumab--mechanism of action and use in clinical practice
    Clifford A Hudis
    Breast Cancer Medicine Service, Solid Tumor Division, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, USA
    N Engl J Med 357:39-51. 2007
  13. ncbi Current status of the taxanes as adjuvant therapy for breast cancer
    Clifford Hudis
    Solid Tumor Division, Department of Medicine, Memorial Sloan Kettering Cancer Center, MSKCC, 1275 York Avenue, New York, NY, USA
    Breast 16:S132-5. 2007
    ..These trials are generally positive but do not clearly identify a single best or ideal regimen for all patients. This paper reviews the available data in this area of clinical research...
  14. ncbi Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system
    Clifford A Hudis
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 25:2127-32. 2007
    ....
  15. ncbi A phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxane
    Shanu Modi
    Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
    Clin Breast Cancer 6:55-60. 2005
    ..The activity and safety reported in this trial are consistent with previous reports in similar patients...
  16. ncbi A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer
    Heather L McArthur
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York 10065, USA
    Clin Cancer Res 17:3398-407. 2011
    ..We evaluated the cardiac safety of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (ddAC) → nanoparticle albumin-bound (nab)-paclitaxel in human epidermal growth factor receptor 2 normal early-stage breast cancer...
  17. ncbi Pioglitazone, a PPARγ agonist, suppresses CYP19 transcription: evidence for involvement of 15-hydroxyprostaglandin dehydrogenase and BRCA1
    Kotha Subbaramaiah
    Department of Medicine, Weill Cornell Cancer Center, New York, NY 10065, USA
    Cancer Prev Res (Phila) 5:1183-94. 2012
    ..PPARγ agonists may have a role in reducing the risk of hormone-dependent breast cancer in obese postmenopausal women...
  18. ncbi Phase II study of feasibility of dose-dense FEC followed by alternating weekly taxanes in high-risk, four or more node-positive breast cancer
    Chau T Dang
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Clin Cancer Res 10:5754-61. 2004
    ..The primary objective was to determine the feasibility of the regimen; the secondary objective was to estimate the disease-free and overall survival...
  19. ncbi Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer
    Alison K Conlin
    Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Clin Breast Cancer 10:281-7. 2010
    ....
  20. ncbi Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer
    Devika Gajria
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, 300 East 66th Street, New York, NY 10065, USA
    Breast Cancer Res Treat 131:111-6. 2012
    ..Capecitabine 7-7 with lapatinib was well tolerated with minimal gastrointestinal toxicity. Antitumor activity was observed in patients with trastuzumab-refractory MBC...
  21. ncbi A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer
    Maura N Dickler
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 14:7878-83. 2008
    ..To evaluate the efficacy and toxicity of erlotinib plus bevacizumab in patients with metastatic breast cancer (MBC), targeting the epidermal growth factor receptor (EGFR/HER1) and the vascular endothelial growth factor (VEGF) pathway...
  22. ncbi Phosphorylated/activated HER2 as a marker of clinical resistance to single agent taxane chemotherapy for metastatic breast cancer
    Shanu Modi
    Memorial Sloan-Kettering Cancer Center, New York, New York, USA
    Cancer Invest 23:483-7. 2005
    ..046). Functional assessment of HER2 status may provide unique predictive information not seen with conventional assessments...
  23. ncbi Phase 2 trial of a novel capecitabine dosing schedule in combination with bevacizumab for patients with metastatic breast cancer
    Devika Gajria
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Cancer 117:4125-31. 2011
    ..Bevacizumab has demonstrated the ability to improve outcomes when it is added to chemotherapy, including capecitabine, in the first-line and second-line settings...
  24. ncbi Inflammation and increased aromatase expression occur in the breast tissue of obese women with breast cancer
    Patrick G Morris
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Cancer Prev Res (Phila) 4:1021-9. 2011
    ..The presence of CLS-B may be a biomarker of increased breast cancer risk or poor prognosis...
  25. ncbi Dose-dense adjuvant Doxorubicin and cyclophosphamide is not associated with frequent short-term changes in left ventricular ejection fraction
    Patrick G Morris
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Clin Oncol 27:6117-23. 2009
    ..Dose-dense (dd) AC followed by paclitaxel (P) is superior to the same regimen given every third week. Herein, we report the early cardiac safety of three sequential studies of ddAC alone or with bevacizumab (B)...
  26. ncbi Radiation pneumonitis in breast cancer patients treated with taxanes: does sequential radiation therapy lower the risk?
    Kathryn Beal
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Breast J 11:317-20. 2005
    ..Sequencing of RT after taxane therapy with a target interval of 3-4 weeks does not appear to result in increased pulmonary toxicity and is associated with good local control...
  27. ncbi Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer
    Heather L McArthur
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Cancer 117:5461-8. 2011
    ..Therefore, a retrospective, single-institution, sequential cohort study of women with small, node-negative, HER2+ breast cancer who did or did not receive adjuvant trastuzumab was conducted...
  28. ncbi Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2: a clinic-based series
    Mark Robson
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 103:44-51. 2005
    ..The current study evaluates the appropriateness of breast-conserving therapy (BCT) in women with BRCA mutations...
  29. ncbi Prolonged dose-dense epirubicin and cyclophosphamide followed by paclitaxel in breast cancer is feasible
    Chau Dang
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Breast Cancer 8:418-24. 2008
    ..Dose-dense EC (without the 5-FU) is not associated with pneumonitis, and dose-dense paclitaxel (alone) is feasible. Primary objective was feasibility...
  30. ncbi Phase II study of celecoxib and trastuzumab in metastatic breast cancer patients who have progressed after prior trastuzumab-based treatments
    Chau T Dang
    Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, USA
    Clin Cancer Res 10:4062-7. 2004
    ..CONCLUSIONS: Celecoxib combined with trastuzumab is well tolerated. However, this combination in patients with HER2/neu-overexpressing, trastuzumab-refractory disease, was not active...
  31. ncbi Serum N-telopeptide and bone-specific alkaline phosphatase levels in patients with osteonecrosis of the jaw receiving bisphosphonates for bone metastases
    Patrick G Morris
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Oral Maxillofac Surg 70:2768-75. 2012
    ..We investigated N-telopeptide of type I collagen (NTX) and bone-specific alkaline phosphatase (BAP) as potential predictors of ONJ onset...
  32. ncbi Standardized uptake value by positron emission tomography/computed tomography as a prognostic variable in metastatic breast cancer
    Patrick G Morris
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer 118:5454-62. 2012
    ....
  33. ncbi A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer
    Shanu Modi
    Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
    Breast Cancer Res Treat 90:157-63. 2005
    ..CONCLUSION: Imatinib therapy at doses of 800 mg/day was associated with significant toxicity in patients with heavily pre-treated MBC. Our results do not indicate activity for imatinib monotherapy in these unselected patients...
  34. ncbi Dose-dense therapy in the treatment of early-stage breast cancer: an overview of the data
    Heather L McArthur
    Breast Cancer Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Clin Breast Cancer 8:S6-S10. 2007
    ..Dose density has since been applied to a number of other chemotherapy regimens and evaluated in clinical trials. An overview of the pivotal dose-dense trials will be reviewed herein...
  35. ncbi Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib
    Patrick G Morris
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Clin Cancer Res 17:3490-9. 2011
    ....
  36. ncbi Mastectomy with immediate expander-implant reconstruction, adjuvant chemotherapy, and radiation for stage II-III breast cancer: treatment intervals and clinical outcomes
    Jean L Wright
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Int J Radiat Oncol Biol Phys 70:43-50. 2008
    ....
  37. ncbi Limited overall survival in patients with brain metastases from triple negative breast cancer
    Patrick G Morris
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Breast J 18:345-50. 2012
    ..This single-institution, retrospective study confirms that the prognosis for patients with BMs from TNBC remains poor. This group of patients urgently needs improved therapies...
  38. ncbi Adjuvant trastuzumab reduces locoregional recurrence in women who receive breast-conservation therapy for lymph node-negative, human epidermal growth factor receptor 2-positive breast cancer
    Ana P Kiess
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer 118:1982-8. 2012
    ..In this sequential, retrospective study, the authors evaluated whether adjuvant trastuzumab was associated with reduced LRR in women with lymph node-negative, HER2-positive disease who received breast-conservation therapy (BCT)...
  39. ncbi Increased levels of COX-2 and prostaglandin E2 contribute to elevated aromatase expression in inflamed breast tissue of obese women
    Kotha Subbaramaiah
    Department of Medicine, Weill Cornell Medical College, New York, New York 10065, USA
    Cancer Discov 2:356-65. 2012
    ..These findings help to explain the link among obesity, low-grade chronic inflammation, and breast cancer with important clinical implications...
  40. ncbi A tool for predicting breast carcinoma mortality in women who do not receive adjuvant therapy
    Michael W Kattan
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer 101:2509-15. 2004
    ....
  41. ncbi Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancer
    Tiffany A Traina
    Breast Cancer Medicine Service, Departments of Radiology, Biostatistics, and Renal Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 28:628-33. 2010
    ..We therefore performed a feasibility study to evaluate the safety of letrozole plus bevacizumab in patients with hormone receptor-positive metastatic breast cancer (MBC)...
  42. ncbi Caloric restriction reverses obesity-induced mammary gland inflammation in mice
    Priya Bhardwaj
    Department of Medicine, Weill Cornell Medical College, 525 East 68th St, Room F 206, New York, NY 10065
    Cancer Prev Res (Phila) 6:282-9. 2013
    ..Our results provide a rationale for determining whether weight loss can reverse breast inflammation associated with obesity in women. Cancer Prev Res; 6(4); 282-9. ©2013 AACR...
  43. ncbi Favorable prognosis in patients with T1a/T1bN0 triple-negative breast cancers treated with multimodality therapy
    Alice Y Ho
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Cancer 118:4944-52. 2012
    ..The authors evaluated the clinical characteristics, natural history, and outcomes of patients who had ≤1 cm, lymph node-negative, triple-negative breast cancer (TNBC)...
  44. ncbi Adjuvant endocrine therapy in hormone receptor-positive postmenopausal breast cancer: evolution of NCCN, ASCO, and St Gallen recommendations
    Robert W Carlson
    Department of Medicine, Stanford University, 875 Blake Wilbur Drive, Stanford, CA 94305 5826, USA
    J Natl Compr Canc Netw 4:971-9. 2006
    ....
  45. ncbi Adjuvant chemotherapy for early-stage breast cancer
    Heather L McArthur
    Breast Cancer Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Hematol Oncol Clin North Am 21:207-22. 2007
    ....
  46. ncbi Breast cancer chemotherapy
    Heather L McArthur
    Breast Cancer Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer J 13:141-7. 2007
    ..In this article we will review the role of important prognostic and predictive factors and the rationale for adjuvant systemic therapy and modern chemotherapy regimens in the management of women with early-stage breast cancer...
  47. ncbi Therapeutic options for metastatic breast cancer
    Patrick G Morris
    Memorial Sloan Kettering Cancer Center, Breast Cancer Medicine Service, NY 10065, New York, USA
    Expert Opin Pharmacother 10:967-81. 2009
    ..We hope that further progress elucidating the pathophysiology and biology of MBC will continue to lead to corresponding advances in treatment...
  48. ncbi Personalizing therapy for metastatic breast cancer
    Patrick G Morris
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Expert Rev Anticancer Ther 9:1223-6. 2009
    ..This article covers key new areas of systemic therapy for MBC from the American Society of Clinical Oncology 2009 annual meeting...
  49. ncbi Optimizing chemotherapy dose and schedule by Norton-Simon mathematical modeling
    Tiffany A Traina
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Breast Dis 31:7-18. 2010
    ..to hasten and improve anticancer drug development, we created a novel approach to generating and analyzing preclinical dose-scheduling data so as to optimize benefit-to-toxicity ratios...
  50. ncbi Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study
    Shanu Modi
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 25:5410-7. 2007
    ..This phase I study examined whether a heat shock protein (Hsp) 90 inhibitor tanespimycin (17-AAG; KOS-953) could be administered safely in combination with trastuzumab at a dose that inhibits Hsp90 function in vivo in lymphocytes...
  51. ncbi Epithelial lesions in prophylactic mastectomy specimens from women with BRCA mutations
    Noah D Kauff
    Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
    Cancer 97:1601-8. 2003
    ..This finding suggests that hereditary breast carcinoma has a preinvasive phase that may be detectable with aggressive surveillance...
  52. ncbi Increased Levels of Urinary PGE-M, a Biomarker of Inflammation, Occur in Association with Obesity, Aging, and Lung Metastases in Patients with Breast Cancer
    Patrick G Morris
    Weill Cornell Medical College, 525 East 68th St, Room F 206, New York, NY 10065 Phone 212 746 4403 Fax 212 746 4885 and Patrick G Morris, Department of Medicine, Memorial Sloan Kettering Cancer Center, 300 E 66th St, New York, NY 10065
    Cancer Prev Res (Phila) 6:428-36. 2013
    ..Cancer Prev Res; 6(5); 428-36. ©2013 AACR...
  53. ncbi Intravenous bisphosphonate therapy does not acutely alter nuclear bone scan results
    Patrick G Morris
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Clin Breast Cancer 10:33-9. 2010
    ..A prospective clinical study was designed to explore this hypothesis. Patients and..
  54. ncbi Integrated positron emission tomography/computed tomography may render bone scintigraphy unnecessary to investigate suspected metastatic breast cancer
    Patrick G Morris
    Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Clin Oncol 28:3154-9. 2010
    ..In this retrospective, single-institution study, we compare the diagnostic performance of integrated positron emission tomography/computed tomography (PET/CT) and bone scintigraphy (BSc) in women with suspected MBC...
  55. ncbi High-dose chemotherapy in breast cancer
    Diana E Lake
    Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Drugs 64:1851-60. 2004
    ..However, ongoing study of drug administration intervals, that is, dose-dense therapies, may lead to an approach that allows superior and less toxic treatment for breast cancer...
  56. ncbi Has first-line therapy had an impact on general outcome in metastatic breast cancer?
    Heather L McArthur
    Memorial Sloan Kettering Cancer Center, c o Sherdina Erwin, Breast Cancer Medicine Service, Department of Medicine, 1275 York Ave, New York, NY 10021, USA
    Future Oncol 3:411-8. 2007
    ..One hopes that ongoing innovations, particularly in targeted therapy, will continue to translate into further improvements in this population...
  57. ncbi Randomized, controlled trial of acupuncture for the treatment of hot flashes in breast cancer patients
    Gary Deng
    Memorial Sloan Kettering Cancer Center, 1429 First Ave, New York, NY 10021, USA
    J Clin Oncol 25:5584-90. 2007
    ..To determine the immediate and long-term effects of true acupuncture versus sham acupuncture on hot flash frequency in women with breast cancer...
  58. ncbi Trastuzumab: a picky partner?
    Heather L McArthur
    Breast Cancer Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Clin Cancer Res 15:6311-3. 2009
    ..Building on this advance will likely depend on elucidation of relevant signaling pathways and mechanisms of action for effective HER2-targeted therapies...
  59. ncbi Latent bone metastasis in breast cancer tied to Src-dependent survival signals
    Xiang H F Zhang
    Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer Cell 16:67-78. 2009
    ..Breast cancer cells that lodge in the bone marrow succumb in this environment when deprived of Src activity...
  60. ncbi Cancer and leukemia group B breast committee: decades of progress and plans for the future
    Clifford A Hudis
    Memorial Sloan-Kettering Cancer Center, New York, New York and Dana-Farber Cancer Institute, Boston, Massachusetts, USA
    Clin Cancer Res 12:3576s-80s. 2006
    ..Current and future projects are aimed at exploiting and increasing our growing knowledge of the molecular biology of breast cancer by developing targeted therapies...
  61. ncbi Advances in adjuvant chemotherapy of early stage breast cancer
    Heather L McArthur
    Breast Cancer Medicine Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
    Cancer Treat Res 141:37-53. 2008
  62. ncbi Prospective exploratory analysis of the association between tumor response, quality of life, and expenditures among patients receiving paclitaxel monotherapy for refractory metastatic breast cancer
    Shanu Modi
    Breast Cancer Medicine Service, Department of Biostatistics and Epidemiology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 20:3665-73. 2002
    ..07). CONCLUSION: Patients with evidence of tumor response on paclitaxel had a QoL benefit not observed in nonresponders, and this response was associated with a trend for lower overall costs...
  63. ncbi A phase I study of cetuximab/paclitaxel in patients with advanced-stage breast cancer
    Shanu Modi
    Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
    Clin Breast Cancer 7:270-7. 2006
    ....
  64. ncbi Current or recent pregnancy is associated with adverse pathologic features but not impaired survival in early breast cancer
    Conleth G Murphy
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Cancer 118:3254-9. 2012
    ..Conflicting data exist regarding the impact of pregnancy on clinical features and prognosis of breast cancer...
  65. ncbi Potential role of selective COX-2 inhibitors in cancer management
    Chau T Dang
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Oncology (Williston Park) 16:30-6. 2002
    ..Clinical trials using targeted inhibitors of COX-2 will be critical in determining if COX-2 is a viable molecular target in cancer management...
  66. ncbi Risk models for neutropenia in patients with breast cancer
    Chau T Dang
    Breast Cancer Medical Service, Memorial Sloan Kettering, Cancer Center, New York, New York, USA
    Oncology (Williston Park) 17:14-20. 2003
    ..These findings could lead to changes in how early-stage breast cancer is managed...
  67. ncbi Postmastectomy intensity modulated radiation therapy following immediate expander-implant reconstruction
    Lawrence Koutcher
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, NY 10065, USA
    Radiother Oncol 94:319-23. 2010
    ..To evaluate radiation plans of patients undergoing mastectomy with immediate expander-implant reconstruction followed by postmastectomy radiation therapy (PMRT)...
  68. ncbi Phase I study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancer
    Tiffany A Traina
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 26:1797-802. 2008
    ....
  69. ncbi A pilot study of dose-dense adjuvant paclitaxel without growth factor support for women with early breast carcinoma
    Steven Sugarman
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Breast Cancer Res Treat 115:609-12. 2009
    ....
  70. ncbi Adjuvant chemotherapy for primary breast cancer
    Monica Fornier
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 457, New York, NY 10021, USA
    Curr Oncol Rep 7:18-22. 2005
    ..This overview provides a summary of the state of the art and the most recent developments regarding adjuvant chemotherapy for primary breast carcinoma...
  71. ncbi Cytokeratin-positive cells in sentinel lymph nodes in breast cancer are not random events: experience in patients undergoing prophylactic mastectomy
    Tari A King
    Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer 101:926-33. 2004
    ..In the current study, we address this question by examining the pattern of SLN involvement in patients undergoing prophylactic mastectomy (PM) at Memorial Sloan-Kettering Cancer Center (New York, NY)...
  72. ncbi Phase I study of nonpegylated liposomal doxorubicin plus trastuzumab in patients with HER2-positive breast cancer
    Maria Theodoulou
    Division of Solid Tumor Oncology, Department of Medicine, Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021 6007, USA
    Clin Breast Cancer 9:101-7. 2009
    ....
  73. ncbi Patterns of toxicity in older patients with breast cancer receiving adjuvant chemotherapy
    Arti Hurria
    Memorial Sloan Kettering Cancer Center, NY 10021, New York, USA
    Breast Cancer Res Treat 92:151-6. 2005
    ..To retrospectively determine the relationship of age to toxicity from adjuvant chemotherapy for breast cancer...
  74. ncbi Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea
    Chau Dang
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 28:2982-8. 2010
    ..We conducted a pilot study of dose-dense AC followed by PT plus lapatinib (PTL) followed by trastuzumab plus lapatinib (TL)...
  75. ncbi Cardiac dysfunction in the trastuzumab clinical trials experience
    Andrew Seidman
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 20:1215-21. 2002
    ....
  76. ncbi Assessment of molecular markers of clinical sensitivity to single-agent taxane therapy for metastatic breast cancer
    Catherine Van Poznak
    Breast Cancer Medicine Service, The Pathology Department, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 20:2319-26. 2002
    ..g., HER2, EGFR), and estrogen receptors and progesterone receptors. These molecular markers and their correlation with clinical taxane sensitivity are investigated in this retrospective clinicopathologic study...
  77. ncbi Aromatase inhibitors in breast cancer: an update
    Diana E Lake
    Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer Control 9:490-8. 2002
    ..Tamoxifen has been the endocrine treatment of choice for patients with breast cancer. The development of selective aromatase inhibitors has offered an alternative management approach for patients in whom a hormonal approach is indicated...
  78. ncbi Factors influencing treatment patterns of breast cancer patients age 75 and older
    Arti Hurria
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Crit Rev Oncol Hematol 46:121-6. 2003
    ..To retrospectively determine the factors influencing treatment decisions in older breast cancer patients at a single center...
  79. ncbi Follow-up care of breast cancer survivors
    Arti Hurria
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue 815, New York, NY 10021, USA
    Crit Rev Oncol Hematol 48:89-99. 2003
    ..In this article, we will discuss the principles of follow-up care of the breast cancer survivor...
  80. ncbi Screening chest imaging studies are not effective in the follow-up of breast cancer patients
    Arti Hurria
    Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Oncol Manag 12:13-5. 2003
    ..To determine the utility of chest imaging after adjuvant therapy for breast cancer in detection of recurrent disease...
  81. ncbi Cardiac profiles of liposomal anthracyclines: greater cardiac safety versus conventional doxorubicin?
    Maria Theodoulou
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 100:2052-63. 2004
    ..Recent evidence also suggests that the improved cardiac safety of liposomal doxorubicin formulations is reflected by their successful use in combination with trastuzumab and other chemotherapy agents...
  82. ncbi Dose dense cyclophosphamide, methotrexate, fluorouracil is feasible at 14-day intervals: a pilot study of every-14-day dosing as adjuvant therapy for breast cancer
    Pamela Drullinsky
    Department of Medicine, Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center at Rockville Centre, 1000 North Village Ave, Rockville Centre, NY 11570, USA
    Clin Breast Cancer 10:440-4. 2010
    ..Randomized trials with other regimens demonstrate that dose-dense (DD) scheduling can offer greater efficacy. We investigated the feasibility of administering CMF using a DD schedule...
  83. ncbi Bone scans, bisphosphonates, and a lack of acute changes within the mandible
    Patrick G Morris
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Oral Maxillofac Surg 69:114-9. 2011
    ..We examined this association within a prospective study assessing the effect of IVBPs on radionuclide bone scanning...
  84. ncbi Dose-dense chemotherapy for breast cancer: what does the future hold?
    Patrick G Morris
    Evelyn H Lauder Breast Center, 300 E 66th St, New York, NY 10065, USA
    Future Oncol 6:951-65. 2010
    ..Newer targeted agents may be similarly incorporated into dose-dense regimens to further improve patient outcomes. This article reviews dose-dense therapy and discusses its role as a chemotherapy foundation for additional targeted agents...
  85. ncbi Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leu
    Andrew D Seidman
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Clin Oncol 26:1642-9. 2008
    ..Because inhibition of HER-family signaling had potential efficacy even without HER-2 overexpression, we randomly assigned for trastuzumab in this population...
  86. ncbi Cognitive function of older patients receiving adjuvant chemotherapy for breast cancer: a pilot prospective longitudinal study
    Arti Hurria
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Am Geriatr Soc 54:925-31. 2006
    ..To report on the longitudinal cognitive functioning of older women receiving adjuvant chemotherapy for breast cancer...
  87. ncbi Effect of creatinine clearance on patterns of toxicity in older patients receiving adjuvant chemotherapy for breast cancer
    Arti Hurria
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Drugs Aging 22:785-91. 2005
    ..We sought to determine the association between calculated creatinine clearance (CL(CR)) and grade 3 or 4 toxicities during adjuvant chemotherapy in women > or =65 years of age with breast cancer...
  88. ncbi Developing a cancer-specific geriatric assessment: a feasibility study
    Arti Hurria
    Department of Medicine, Psychiatry and Behavioral Sciences, and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 104:1998-2005. 2005
    ....
  89. ncbi A prospective, longitudinal study of the functional status and quality of life of older patients with breast cancer receiving adjuvant chemotherapy
    Arti Hurria
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Am Geriatr Soc 54:1119-24. 2006
    ..To examine the toxicity experienced by a cohort of older women receiving adjuvant chemotherapy for breast cancer and the longitudinal effect on their functional status and quality of life (QOL)...
  90. ncbi Effect of adjuvant breast cancer chemotherapy on cognitive function from the older patient's perspective
    Arti Hurria
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Breast Cancer Res Treat 98:343-8. 2006
    ..This longitudinal prospective study describes the older breast cancer patient's perception of the cognitive impact of adjuvant chemotherapy...
  91. ncbi Immunization of high-risk breast cancer patients with clustered sTn-KLH conjugate plus the immunologic adjuvant QS-21
    Teresa A Gilewski
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 13:2977-85. 2007
    ..To determine the clinical toxicities and antibody response against sTn and tumor cells expressing sTn following immunization of high-risk breast cancer patients with clustered sTn-KLH [sTn(c)-KLH] conjugate plus QS-21...
  92. ncbi Increased dose density is feasible: a pilot study of adjuvant epirubicin and cyclophosphamide followed by paclitaxel, at 10- or 11-day intervals with filgrastim support in women with breast cancer
    Monica N Fornier
    Breast Cancer Medicine Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 13:223-7. 2007
    ..We conducted a pilot trial to assess the feasibility of dose-dense chemotherapy consisting of a standard regime at 10- to 11-day intervals in the adjuvant/neoadjuvant setting. A 2-day window was allowed for scheduling logistics...
  93. ncbi Adjuvant treatment recommendations in older women with breast cancer: a survey of oncologists
    Arti Hurria
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Crit Rev Oncol Hematol 61:255-60. 2007
    ..Previous studies demonstrate differing treatment patterns between older and younger patients with breast cancer. To explore the reasons for these disparities we conducted a survey of 28 oncologists specializing in breast cancer...
  94. ncbi Pharmacokinetics and toxicity of weekly docetaxel in older patients
    Arti Hurria
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, New York 10021, USA
    Clin Cancer Res 12:6100-5. 2006
    ....
  95. ncbi The effect of changes in tumor size on breast carcinoma survival in the U.S.: 1975-1999
    Elena B Elkin
    Health Outcomes Research Group, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer 104:1149-57. 2005
    ..The objective of the current study was to characterize within-stage migration of tumor size in breast carcinoma, and to estimate the effect of this shift on reported breast carcinoma survival...
  96. ncbi Adjuvant taxanes in the treatment of breast cancer: no longer at the tip of the iceberg
    Chau Dang
    Department of Medicine, Breast Cancer Medicine Service Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Breast Cancer 7:51-8. 2006
    ..Thus, taxanes should be incorporated into the adjuvant treatment of breast cancer. To date, the available data do not allow one to select a single best taxane, schedule, or overall regimen...
  97. ncbi Occult axillary node metastases in breast cancer are prognostically significant: results in 368 node-negative patients with 20-year follow-up
    Lee K Tan
    Department of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Clin Oncol 26:1803-9. 2008
    ..However, there is no consensus regarding the optimal method for pathologic examination of SLN, or the prognostic significance of SLN micrometastases...
  98. ncbi Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study
    Noah D Kauff
    Clinical Genetics and Gynecology Services, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 192, New York, NY 10021, USA
    J Clin Oncol 26:1331-7. 2008
    ....
  99. ncbi The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer
    Chau Dang
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Howard 713, New York, NY 10021, USA
    J Clin Oncol 26:1216-22. 2008
    ..The primary end point was cardiac safety, and the secondary end points were time to recurrence and overall survival...
  100. ncbi The prostaglandin transporter regulates adipogenesis and aromatase transcription
    Kotha Subbaramaiah
    Department of Medicine, Weill Cornell Medical College, New York, NY 10065, USA
    Cancer Prev Res (Phila) 4:194-206. 2011
    ..Collectively, these results suggest that PGT modulates adipogenesis and thereby PGE(2)-mediated activation of the cAMP → PKA → CREB pathway leading to altered CYP19 transcription and aromatase activity...
  101. ncbi Return to work in low-income Latina and non-Latina white breast cancer survivors: a 3-year longitudinal study
    Victoria S Blinder
    Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer 118:1664-74. 2012
    ..We set out to compare the trajectories of low-income Latina and non-Latina white survivors and to identify correlates of employment status...

Research Grants3

  1. CANCER AND LEUKEMIA GROUP B
    Clifford Hudis; Fiscal Year: 2007
    ..The enclosed grant will provide resources for continued participation in the CALGB and for increased contributions by MSKCC to the group's success. ..